The U.S. FDA has approved a drug that could extend the survival of people with metastatic pancreatic cancer.
-
The U.S. FDA has approved a drug that could extend the survival of people with metastatic pancreatic cancer. In a clinical trial, median overall survival doubled to more than 13 months compared to chemotherapy. Here's more from @abc.
-
T #medicine shared this topic
-
The U.S. FDA has approved a drug that could extend the survival of people with metastatic pancreatic cancer. In a clinical trial, median overall survival doubled to more than 13 months compared to chemotherapy. Here's more from @abc.
@ScienceDesk @abc It seems the usual overblown neoadjuvant drug, costly, difficult to obtain and linked with specific subset of patients. So far, we must admit that it is only a matter of mega-profits and less about survival of oncology patients.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better đź’—
Register Login